Clinical Spectrum of Bosutinib Related Side Effects in a Patient of CML: A Case Report and Review of Literature

Vishnu Sharma; Sidharth Mahajan; Vansh Bagrodia; Jahanvi Grover; Vaibhav Oberoi

doi:10.18502/ijhoscr.v19i3.19291

Vishnu Sharma Department of General Medicine, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India
Sidharth Mahajan Government Medical College, Amritsar, India
Vansh Bagrodia Department of General Medicine, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India
Jahanvi Grover PGIMS, Rohtak, India
Vaibhav Oberoi Government Medical College, Amritsar, India

DOI: https://doi.org/10.18502/ijhoscr.v19i3.19291

Keywords: Bosutinib; Chronic myeloid leukemia; Bosutinib toxicity; Pulmonary arterial hypertension; Pleural effusion

Abstract

This case study outlines the complex treatment journey of a 53-year-old male diagnosed with Chronic Myeloid Leukemia (CML). Despite initial therapy with Imatinib and a subsequent switch to Dasatinib and then Bosutinib due to treatment resistance and adverse effects, the patient experienced multiple unexpected complications, including bilateral pleural effusions, pulmonary arterial hypertension, renal impairment, and neurological symptoms. Bosutinib was identified as the likely cause, leading to its discontinuation and transition to Nilotinib, which resulted in a sustained molecular response without further adverse events. Through this case report and literature review, we aim to expand the dimensions of the toxicity profile of bosutinib.